A- A A+

WHO. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection

WHO, Number of pages: 108; Publication date: July 2018; Languages: English; ISBN: 978-92-4-155034-5

These guidelines aim to provide evidence-based recommendations on the care and treatment of persons diagnosed with chronic HCV infection. They update the care and treatment section of the WHO Guidelines for the screening, care and treatment of persons with hepatitis C infection issued in April 2016. The 2017 Guidelines on hepatitis B and C testing update the screening section.


A survey of tobacco dependence treatment guidelines content in 61 countries

Kapka Nilan, Ann McNeill, Rachael L. Murray, Tricia M. McKeever and Martin Raw 

Addiction, Volume 113, Issue8, August 2018, Pages 1499-1506

First published: 28 February 2018, doi.org/10.1111/add.14204


Simplified guideline for prescribing medical cannabinoids in primary care. 

Allan GM, Ramji J, Perry D, Ton J, Beahm NP, Crisp N, et al. 

Can Fam Physician. 2018;64:111–20. (Eng), e64–75 (Fr).


Inpatient and Outpatient Treatment Programs for Substance Use Disorder: A Review of Clinical Effectiveness and Guidelines [Internet].

Ho C, Adcock L.

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Nov 7.


Deutsch-Österreichische Leitlinien zur HIV-Präexpositionsprophylaxe

Klassifikation: S2k, AWMF-Register-Nr.: 055-008, Federführung: Deutsche AIDS-Gesellschaft (DAIG), 24.5.2018


USA. Scientific guidelines for using cannabis to treat stress, anxiety and depression

PULLMAN, Wash.--In a first-of-a-kind study, Washington State University scientists examined how peoples' self-reported levels of stress, anxiety and depression were affected by smoking different strains and quantities of cannabis at home. (Washington State University, 19.04.2018)


Open letter on the UNODC/WHO International Standards for the Treatment of Drug Use Disorders

We, the undersigned civil society organisations working at the national, regional and international level on issues related to drug use, drug treatment, harm reduction and drug policies, are writing to you today regarding the joint UNODC and WHO publication entitled International Standards for the Treatment of Drug Use Disorders.

The ‘Draft for Field Testing’ of this document (March 2017) raises serious concerns and contains significant omissions and misrepresentations. We request your urgent action to prevent these Standards being released in their current state. (Unterzeichnet von 188 Organisationen, 08.03.2018)


International Consensus Statement on Screening, Diagnosis and Treatment of Substance Use Disorder Patients with Comorbid Attention Deficit/Hyperactivity Disorder.

Crunelle CL, van den Brink W, Moggi F, Konstenius M, Franck J, Levin FR, van de Glind G, Demetrovics Z, Coetzee C, Luderer M, Schellekens A; ICASA consensus group, Matthys F.

Eur Addict Res. 2018;24(1):43-51. doi: 10.1159/000487767.


Cannabinoid Hyperemesis Syndrome: Public Health Implications and a Novel Model Treatment Guideline.

Lapoint J, Meyer S, Yu CK, Koenig KL, Lev R, Thihalolipavan S, Staats K, Kahn CA.

West J Emerg Med. 2018 Mar;19(2):380-386. doi: 10.5811/westjem.2017.11.36368.


Niederlande. Richtlijnen: Stoornissen in het gebruik van cannabis, cocaïne, amfetamine, ecstasy, GHB en benzodiazepines

(GGZ Standaarden - Dé online database met alle zorgstandaarden, richtlijnen en generieke modules,Niederlande, 26.02.2018)


Kanada. Management of opioid use disorders: a national clinical practice guideline

Julie Bruneau, Keith Ahamad, Marie-Ève Goyer, Ginette Poulin, Peter Selby, Benedikt Fischer, T. Cameron Wild and Evan Wood; on behalf of the CIHR Canadian Research Initiative in Substance Misuse

CMAJ March 05, 2018 190 (9) E247-E257; doi.org/10.1503/cmaj.170958


Kanada. Best Practice Guidelines: Implementing Supervised Injection Services

(Registered Nurses’ Association of Ontario, Februar 2018)


USA. SAMHSA publishes guidance on clinical best practices using medication-assisted treatment to combat the opioid epidemic

The Substance Abuse and Mental Health Services Administration (SAMHSA) is publishing guidance today to help broaden healthcare professionals’ understanding of medications that can be used to treat Americans with opioid use disorder (OUD).

“We know that people can and do recover from opioid use disorders when they receive appropriate treatment, and medication-assisted treatment’s success in treating opioid use disorders is well documented,” said Dr. Elinore F. McCance-Katz, Assistant Secretary for Mental Health and Substance Use. “TIP 63 emphasizes that increasing access to medications to treat opioid use disorder will help more people recover, enabling them to improve their health, living full and productive lives.”

The Treatment Improvement Protocol (TIP) 63, “Medications for Opioid Use Disorder,” reviews the use of the three Food and Drug Administration-approved medications to treat opioid use disorders: methadone, naltrexone, and buprenorphine. Mandated by Section 303 of the Comprehensive Addiction and Recovery Act (P.L. 114-198), this TIP provides guidance for healthcare professionals and addiction treatment providers on appropriate prescribing practices for these medications and effective strategies for supporting the patients utilizing medication for the treatment of OUD. TIP 63 also educates patients, families, and the general public about how OUD medications work and the benefits they offer. The Substance Abuse and Mental Health Services Administration (SAMHSA), 15.02.2018)


USA-SAMHSA. TIP 63: Medications for Opioid Use Disorders – Full Document (Including Executive Summary and Parts 1-5)

This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat opioid use disorder (OUD)—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. (SAMHSA), 2/2018)


APA: Pharmacological Treatment of Patients with Alcohol Use Disorder

The Practice Guideline for the Pharmacological Treatment of Patients with Alcohol Use Disorder was approved by the APA Assembly in May and by the APA Board of Trustees July 2017. (APA – American Psychiatric Association, Clinical Practice Guidelines, 05.02.2018)


Handbuch Substitutionsbehandlung in Oberösterreich

Sachverständigenkommission zur regionalen Koordination der Substitutionsbehandlung

Linz, 2016

Version 2.0


Guidelines on the management of co-occurring alcohol and other drug and mental health conditions in alcohol and other drug treatment settings

NHMRC Centre of Research Excellence in Mental Health and Substance Use, National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia; 2016


Deutsch-Österreichische Leitlinien zur Postexpositionellen Prophylaxe der HIV-Infektion

Federführung: Deutsche AIDS-Gesellschaft (DAIG)

unter Beteiligung der folgenden Fachgesellschaften:

•Österreichische AIDS-Gesellschaft (ÖAIG)

•Deutschen AIDS-Hilfe (DAH)

•Bundeszentrale für gesundheitliche Aufklärung (BZgA)

•Nationales Referenzzentrum für Retroviren, Universitätsklinikum Frankfurt

•Robert Koch-Institut (RKI)

•Kompetenznetz HIV/AIDS

Annahme der aktuellen Version durch Mitgliederbeschluss der Deutschen AIDS Gesellschaft (DAIG) am 13.06.2013


UK. Guidance: Drug misuse and dependence: UK guidelines on clinical management - How clinicians should treat people with drug misuse and drug dependence problems.

Published 14 July 2017, Last updated 15 December 2017

Government of UK, Department of Health

This 2017 version offers new guidelines on:

prison-based treatment

new psychoactive substances and club drugs

mental health co-morbidity

misuse of prescribed and over-the-counter medicines

stopping smoking

preventing drug-related deaths, including naloxone provision


Neufassung des Genfer Gelöbnisses liegt auf Deutsch vor

Berlin – Die überarbeitete Fassung des Genfer Gelöbnisses liegt nun auch in deutscher Übersetzung vor. Darauf hat die Bundesärztekammer (BÄK) hingewiesen. Die überarbeitete Version wurde zwischen den deutschsprachigen Mitgliedsverbänden und den Ethikexperten des Weltärztebundes (WMA) abgestimmt. Der WMA hatte im Oktober 2017 eine modernisierte Fassung des hippokratischen Eids für Ärzte verabschiedet. (aerzteblatt.de, 04.12.2017)


Responding to children and adolescents who have been sexually abused - WHO clinical guidelines

Number of pages: 73
Publication date: 2017
Languages: English
ISBN: 978-92-4-155014-7

Sexual abuse of children and adolescents is a gross violation of their rights and a global public health problem. It adversely affects the health of children and adolescents. Health care providers are in a unique position to provide an empathetic response to children and adolescents who have been sexually abused. Such a response can go a long way in helping survivors recover from the trauma of sexual abuse.

WHO has published new clinical guidelines Responding to children and adolescents who have been sexually abused aimed at helping front-line health workers, primarily from low resource settings, in providing evidence-based, quality, trauma-informed care to survivors. The guidelines emphasize the importance of promoting safety, offering choices and respecting the wishes and autonomy of children and adolescents. They cover recommendations for post-rape care and mental health; and approaches to minimizing distress in the process of taking medical history, conducting examination and documenting findings.


Guidance for commissioners, providers and clinicians on the roles of nurses in alcohol and drug treatment in England. (PHE – Public Health England publications gateway number 2017349, UK, 20.10.2017)


Kanada. Guidance for Injectable Opioid Agonist Treatment for Opioid Use Disorder

British Columbia, Ministry of Health and British Columbia Centre on Substance Abuse, 2017


WHO. Guidelines for identification and management of substance use and substance use disorders in pregnancy

WHO - World Health Organization, 2014, ISBN: 9789241548731


Monthly take-home methadone maintenance regime for elderly opium-dependent users in Singapore.

Guo S, Winslow M, Manning V, Thane KK.

Ann Acad Med Singapore. 2010 Jun;39(6):429-34.


Responsible, Safe, and Effective Prescription of Opioids for Chronic Non-Cancer Pain: American Society of Interventional Pain Physicians (ASIPP) Guidelines.

Manchikanti L, Kaye AM, Knezevic NN, McAnally H, Slavin K, Trescot AM, Blank S, Pampati V, Abdi S, Grider JS, Kaye AD, Manchikanti KN, Cordner H, Gharibo CG, Harned ME, Albers SL, Atluri S, Aydin SM, Bakshi S, Barkin RL, Benyamin RM, Boswell MV, Buenaventura RM, Calodney AK, Cedeno DL, Datta S, Deer TR, Fellows B, Galan V, Grami V, Hansen H, Helm Ii S, Justiz R, Koyyalagunta D, Malla Y, Navani A, Nouri KH, Pasupuleti R, Sehgal N, Silverman SM, Simopoulos TT, Singh V, Solanki DR, Staats PS, Vallejo R, Wargo BW, Watanabe A, Hirsch JA.

Pain Physician. 2017 Feb;20(2S):S3-S92.


The American College of Obstetricians and Gynecologists: Opioid Use and Opioid Use Disorder in Pregnancy

Committee Opinion No. 711 Summary

Obstetrics & Gynecology: August 2017 - Volume 130 - Issue 2 - p 488–489

doi: 10.1097/AOG.0000000000002229


UK. Drug misuse and dependence: UK guidelines on clinical management - How clinicians should treat people with drug misuse and drug dependence problems.

Often called the Orange Book, this is guidance for clinicians treating people with drug problems.

This 2017 version offers new guidelines on:

- prison-based treatment

- new psychoactive substances and club drugs

- mental health co-morbidity

- misuse of prescribed and over-the-counter medicines

- stopping smoking

- preventing drug-related deaths, including naloxone provision

The new guidelines also have a stronger emphasis on recovery and a holistic approach to the interventions that can support recovery. (Clinical Guidelines on Drug Misuse and Dependence Update 2017, Independent Expert Working Group (2017) Drug misuse and dependence: UK guidelines on clinical management. London: Department of Health. Department of Health, Drug misuse and dependency, 14.07.2017)